Effectiveness of micro-induction approaches to buprenorphine initiation: A systematic review protocol.
Jessica Moe, Mary M Doyle-Waters, Fiona O'Sullivan...
https://pubmed.ncbi.nlm.nih.gov/32739588/Actively Recruiting
Led by University of British Columbia · Updated on 2026-09-24
658
Participants Needed
6
Research Sites
26 weeks
Total Duration
Researchers are conducting a multi-center, open-label randomized controlled trial at four emergency departments in British Columbia and Alberta to compare two dosing strategies of buprenorphinenaloxone for patients with opioid use disorder. The study aims to evaluate whether microdosing or standard dosing take-home induction regimens lead to better completion of the induction period and longer retention on opioid agonist therapy. The trial also investigates outcomes like overdose, mortality, and healthcare usage after the emergency visit. Participants will be randomly assigned to receive either a microdosing package or a standard dosing package of buprenorphinenaloxone to take home. The microdosing group starts with low doses that increase gradually over five days, while the standard dosing group receives a regimen designed to reach therapeutic doses within 24 hours. Both groups receive adjunctive medications for symptom relief during the induction, and counseling support is offered to address social needs. During the study, participants prescription fills within two weeks will be tracked to confirm induction completion. Retention on opioid therapy and healthcare events including overdoses and hospital visits will be monitored up to one year using provincial health databases. Surveys will collect participants self-reported experiences with withdrawal and comfort. The total study duration includes ongoing follow-up for up to 365 days after the emergency department visit.
CONDITIONS
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
E
Elle Wang, MSc
C
Cindy Liu, BSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of British Columbia
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive a take-home package of buprenorphine/naloxone either using microdosing or standard dosing regimens for five days. Adjunctive medications for symptom relief and counseling support are provided.
1 visit at enrollment and follow-up assessments
Duration - Up to 365 days
Researchers track prescription fills, retention on opioid therapy, overdose events, mortality, and healthcare usage up to 365 days after the emergency visit.
Regular data collection through provincial health records
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jessica Moe, Mary M Doyle-Waters, Fiona O'Sullivan...
https://pubmed.ncbi.nlm.nih.gov/32739588/Jessica Moe, Fiona O'Sullivan, Corinne M Hohl...
https://pubmed.ncbi.nlm.nih.gov/33352498/Jessica Moe, Katherin Badke, Megan Pratt...
https://pubmed.ncbi.nlm.nih.gov/33392580/University of British Columbia
Lead Sponsor